Disease Impact and Perception of Biologics in Adults with Type 2 Inflammation Respiratory Disease: International Survey Results.

PURPOSE

There is a growing interest in developing approaches that reduce the impact of Type 2 inflammatory conditions, such as asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), on well-being. The aim of this international survey was to understand the impact of asthma and CRSwNP on people living with these conditions and to seek insight into the perception of biologics, which are often used to treat them.

PATIENTS AND METHODS

A cross-sectional survey was conducted anonymously online from February to May 2024. International participants were recruited through social media and by Survey Monkey. Individuals aged ≥18 years diagnosed by a medical professional with asthma and/or CRSwNP who lived in the US, Canada, UK, Germany, Italy, France, or Spain were eligible to participate.

RESULTS

Of the 1566 survey participants (56.7% asthma, 24.8% CRSwNP, 18.5% both), 52.5% were female, and 65.3% were ages 25-54 years. Approximately two-thirds (64%) reported thinking once/day or at least once/week about managing their condition. Nearly half (44%) find it difficult to manage their disease. Of those currently using a biologic (14%), only 37% inject it themselves and feel confident doing so, and 42% felt it was a repeating reminder of their chronic condition. The top reason for stopping biologic treatment was that the injection/device was too difficult. The possibility of a lower frequency injection increased the likelihood participants would consider a biologic.

CONCLUSION

The study further raises awareness of the personal burden from asthma and CRSwNP and their associated treatments in different countries. Beyond the goal of achieving clinical disease control for these diseases, a holistic approach to care delivery should include culturally appropriate emotional health support to improve overall well-being. Access to biologics administered with less frequency may alleviate some of the burden of self-injection.